Performance Evaluation of a New Automated Chemiluminescent Immunoanalyzer-Based Interferon-Gamma Releasing Assay AdvanSure I3 in Comparison With the QuantiFERON-TB Gold In‑Tube Assay
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The interferon-gamma (IFN-γ) releasing assay (IGRA) is widely used for latent tuberculosis infection (LTBI) diagnosis. We evaluated the analytical performance of a new automated chemiluminescent immunoanalyzer-based IGRA (CLIA-IGRA), AdvanSure I3 (LG Life Sciences, Seoul, Korea) and compared it with that of the QuantiFERON-TB Gold In‑Tube (QFT-GIT) assay. Methods: Repeatability and reproducibility were evaluated at four levels. Detection capability, including limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ), was evaluated using IFN-γ standard material (National Institute for Biological Standards and Control code: 87/586). Agreement between the results of two assays was evaluated using 341 blood samples from healthcare workers and patients at a tertiary care hospital. To determine the cut-off value of CLIA-IGRA for diagnosing LTBI, the ROC curve was analyzed. Results: Repeatability and reproducibility were 4.86–7.00% and 6.36–7.88% CV, respectively. LoB, LoD, and LoQ were 0.022, 0.077, and 0.249 IU/mL, respectively. IFN-γ values between CLIA-IGRA and QFT-GIT showed a strong correlation within the analytical measurable range of both assays, especially when the value was low. Qualitative comparison of the two assays yielded a 99.1% overall agreement (kappa coefficient=0.98). A cut-off value of 0.35 IU/mL was appropriate for diagnosing LTBI. Conclusions: CLIA-IGRA is a reliable assay for LTBI diagnosis, with performance similar to that of QFT-GIT.
Abstract
Background: The interferon-gamma (IFN-γ) releasing assay (IGRA) is widely used for latent tuberculosis infection (LTBI) diagnosis. We evaluated the analytical performance of a new automated chemiluminescent immunoanalyzer-based IGRA (CLIA-IGRA), AdvanSure I3 (LG Life Sciences, Seoul, Korea) and compared it with that of the QuantiFERON-TB Gold In‑Tube (QFT-GIT) assay. Methods: Repeatability and reproducibility were evaluated at four levels. Detection capability, including limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ), was evaluated using IFN-γ standard material (National Institute for Biological Standards and Control code: 87/586). Agreement between the results of two assays was evaluated using 341 blood samples from healthcare workers and patients at a tertiary care hospital. To determine the cut-off value of CLIA-IGRA for diagnosing LTBI, the ROC curve was analyzed. Results: Repeatability and reproducibility were 4.86–7.00% and 6.36–7.88% CV, respectively. LoB, LoD, and LoQ were 0.022, 0.077, and 0.249 IU/mL, respectively. IFN-γ values between CLIA-IGRA and QFT-GIT showed a strong correlation within the analytical measurable range of both assays, especially when the value was low. Qualitative comparison of the two assays yielded a 99.1% overall agreement (kappa coefficient=0.98). A cut-off value of 0.35 IU/mL was appropriate for diagnosing LTBI. Conclusions: CLIA-IGRA is a reliable assay for LTBI diagnosis, with performance similar to that of QFT-GIT.
참고문헌 (28)
- "Global tuberculosis report 2018"[URL]
- Ahmad S, "Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection", Clin Dev Immunol, 2011, pp.814943~ (2011)
- Yoo JW, "Comparison of latent tuberculosis infection rate between contacts with active tuberculosis and non-contacts", Respir Med, 111, pp.77~83 (2016)
- Ai JW, "Updates on the risk factors for latent tuberculosis reactivation and their managements", Emerg Microbes Infect, 5, pp.e10~ (2016)
- Mazurek GH, "Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection–United States, 2010", MMWR Recomm Rep, 59, pp.1~25 (2010)
- Menzies D, "Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research", Ann Intern Med, 146, pp.340~354 (2007)
- Ayubi E, "Comparison of QuantiFERON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) for diagnosis of latent tuberculosis in haemodialysis (HD) patients: a meta-analysis of kappa estimates", Epidemiol Infect, 145, pp.1824~1833 (2017)
- Soysal A, "Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection", Int J Tuberc Lung Dis, 12, pp.50~56 (2008)
- CLSI, "Evaluation of precision performance of quantitative measurement methods; approved Guideline" (2014), Clinical and Laboratory Standards Institute
- CLSI, "Protocols for determination of limits of detection and limits of quantitation; approved guideline" (2012), Clinical and Laboratory Standards Institute
- CLSI, "User protocol for evaluation of qualitative test performance; approved guideline" (2008), Clinical and Laboratory Standards Institute
- CLSI, "Measurement procedure comparison and bias estimation using patient samples; approved guideline" (2013), Clinical and Laboratory Standards Institute
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Zhang QY, "Comparison of chemiluminescence enzyme immunoassay based on magnetic microparticles with traditional colorimetric ELISA for the detection of serum alpha-fetoprotein", J Pharm Anal, 2, pp.130~135 (2012)
- Jin H, "Magnetic particle-based chemiluminescence enzyme immunoassay for free thyroxine in human serum", J Pharm Biomed Anal, 50, pp.891~896 (2009)
- Wang X, "Evaluation of carbohydrate antigen 50 in human serum using magnetic particle-based chemiluminescence enzyme immunoassay", Anal Chim Acta, 598, pp.261~267 (2007)
- 우광숙, "Repeatability of QuantiFERON-TB Gold In-Tube Assay Results Near Cut-Off Points", Annals of Laboratory Medicine, 36(1), pp.76~78 (2016), 대한진단검사의학회
- Adetifa IM, "Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection : a clinical trial", Am J Respir Crit Care Med, 187, pp.439~445 (2013)
- Chiappini E, "Utility of interferon-gamma release assay results to monitor anti-tubercular treatment in adults and children", Clin Ther, 34, pp.1041~1048 (2012)
- Hang NT, "Association between tuberculosis recurrence and interferon-γ response during treatment", J Infect, 69, pp.616~626 (2014)
- Clifford V, "Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review", Tuberculosis (Edinb), 95, pp.639~650 (2015)
- Uden L, "Risk of tuberculosis infection and disease for health care workers: an updated meta-analysis", Open Forum Infect Dis, 4, pp.ofx137~ (2017)
- 조경욱, "Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study", Tuberculosis and Respiratory Diseases, 75(1), pp.18~24 (2013), 대한결핵및호흡기학회
- Slater ML, "Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers", Am J Respir Crit Care Med, 188, pp.1005~1010 (2013)
- Pai M, "Occupational screening of health care workers for tuberculosis infection: tuberculin skin testing or interferon-γ release assays?", Occup Med (Lond), 63, pp.458~460 (2013)
- Barcellini L, "First evaluation of QuantiFERON-TB Gold Plus performance in contact screening", Eur Respir J, 48, pp.1411~1419 (2016)
- Petruccioli E, "Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis", Tuberculosis (Edinb), 106, pp.38~43 (2017)
- Hoffmann H, "Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT", Clin Microbiol Infect, 22, pp.701~703 (2016)